| Valuation method | Value, CHF | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 32.00 | 64157 |
| Intrinsic value (DCF) | 0.07 | 41 |
| Graham-Dodd Method | 0.46 | 820 |
| Graham Formula | n/a |
Addex Therapeutics Ltd (ADXN.SW) is a Swiss-based development-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators targeting G-protein coupled receptors (GPCRs) for central nervous system (CNS) disorders. Headquartered in Geneva, the company focuses on innovative treatments for conditions such as Parkinson's disease levodopa-induced dyskinesia, epilepsy, and addiction. Its lead candidates include Dipraglurant, ADX71149, and GABAB PAM, with strategic collaborations with Janssen Pharmaceuticals and Indivior PLC enhancing its research and commercialization potential. Operating in the high-growth biotechnology sector, Addex Therapeutics leverages its expertise in GPCR modulation to address unmet medical needs in neurology and psychiatry. Despite being pre-revenue, the company's strong pipeline and partnerships position it as a promising player in CNS therapeutics.
Addex Therapeutics presents a high-risk, high-reward investment opportunity due to its focus on innovative CNS therapies and strategic collaborations. The company's lead candidate, Dipraglurant, targets a niche market in Parkinson's disease dyskinesia, offering significant upside if clinical trials succeed. However, as a development-stage biotech, Addex faces substantial risks, including clinical trial failures, regulatory hurdles, and cash burn (evidenced by negative operating cash flow of CHF -5.37M in the latest period). With a market cap of ~CHF 10.7M and high beta (2.022), the stock is highly volatile and suited for speculative investors comfortable with biotech sector risks. The lack of revenue diversification and reliance on partnership milestones further amplify uncertainty.
Addex Therapeutics competes in the highly competitive CNS disorder therapeutics market, where differentiation hinges on clinical efficacy, safety profiles, and commercialization partnerships. The company's competitive edge lies in its specialized focus on allosteric modulators of GPCRs—a complex but promising mechanism that could offer advantages over traditional orthosteric drugs in terms of selectivity and side-effect profiles. However, Addex faces intense competition from larger biopharma firms with deeper pipelines and financial resources. Its collaboration with Janssen (a Johnson & Johnson subsidiary) provides validation and funding but also exposes Addex to dependency risks. The company's small size limits its ability to independently bring drugs to market, necessitating further partnerships or licensing deals. While its niche focus on dyskinesia and epilepsy could reduce direct competition in specific indications, it also narrows its market opportunity. Success will depend on clinical data readouts and the ability to secure additional funding or partnerships to advance its pipeline.